# Zephyr Platform: Transforming Complex Data into Actionable Insights

## Built for Real-World Impact

The Zephyr Platform combines **multi-modal AI, enterprise-scale real-world data**, and **deeply profiled oncology cohorts**—delivered on secure, compliant infrastructure built for speed and scale. Our solutions integrate seamlessly into partner workflows to **de-risk development, optimize patient selection, and accelerate clinical translation**—driving solutions from **discovery to deployment**.

### AIM Suite: Multi-Modal AI for Precision Oncology

#### Flexible AI modules tailored to partner needs—real-world validated, interpretable, and ready to deploy.

The AIM Suite is a set of modular, biologically interpretable AI tools designed to integrate seamlessly into R&D workflows—no new assays required. Each module can operate independently or be combined, giving partners the flexibility to tailor solutions to their drug development or clinical needs.

**AIM-Bx & AIM-io**  
Predict response to small molecules or immune checkpoint inhibitors using clinically available data. Validated in real-world cohorts, outperforming conventional biomarkers, and adaptable as AI-CDx for partner drugs.

**AIM-CDx**  
Fine-tuned companion diagnostics co-developed with biopharma and diagnostics partners. Built on AIM-Bx and adapted to partner assays and assets with preclinical or clinical data.

**AIM-Ex**  
Reconstructs mRNA expression from DNA-based LDTs and minimal clinical data with high concordance to RNAseq. Enhances interpretability and feeds downstream models with biologically rich expression-level inputs.

### Nexus: Real-World Intelligence at Scale

#### Linking multimodal real-world data to discovery, validation, and market strategy.

Nexus **transforms EHR, claims, genomics, and pathology data** into **actionable insights** for discovery, validation, and market strategy.

**Analytics & Insights**  
Extract intelligence from 90M+ patients across oncology (1M+ with NGS) and chronic disease.

**Cohort Construction & Synthetic Controls**  
Define fit-for-purpose populations and credible comparator arms for trials and HEOR.

**AI/ML Modeling & Validation**  
Train, test, and refine predictive models on linked longitudinal data.

**Intervention-Specific Risk Modeling**  
Predict outcomes and costs to inform pricing, access, and value-based care strategies.

### Deep Oncology Data: Curated, Consented Cancer Cohorts

#### One of the world’s largest deeply profiled oncology resources, enabling discovery and validation at scale.

Through Aster Insights™ and the ORIEN Total Cancer Care® study, Zephyr provides access to one of the largest and most deeply profiled oncology resources in the world—400K+ lifetime-consented patients across leading cancer centers.

**Linked, Multi-Modal Profiles**  
Aster Avatar: matched clinical, exome, transcriptome, and digital pathology data with longitudinal updates–ideal for translational research and biomarker discovery.

**Fit-for-Purpose Data Generation**  
Generate new molecular data to power discovery, validation, and regulatory programs.

### Enterprise-Grade Infrastructure for Speed and Scale

#### Built for pharma-grade security and speed—SOC 2 & HIPAA compliant, fast to pilot, and scalable to impact.

Zephyr is built to meet the highest standards of security, compliance, and scalability—going far beyond academic or point-solution approaches. With SOC 2 and HIPAA compliance, partner data is handled securely and responsibly.

**Modern ML Ops lifecycle management and deployment systems**  
Our investment in these systems means models move seamlessly from concept to production.

**Fast to start, scalable to impact**  
Zephyr can launch proof-of-concept pilots in weeks and scale them to clinical and commercial applications without re-engineering.

### The Power of Our Platform, Tailored to You

Zephyr’s platform bridges experimental and clinical domains, extracting hidden signals from large multi-modal datasets to deliver actionable insights that drive discovery, validation, and co-development. Partners benefit from models enriched with deep biological context—shaped by learnings across vast drug, tumor, and patient landscapes—yet adaptable and fine-tunable to their unique assets.

- Clinically validated across diverse, real-world patient cohorts
- Seamlessly compatible with existing diagnostics—no new assays required
- Biologically interpretable outputs that support trust and regulatory alignment
- Flexible and adaptable—retrospective or prospective validation, fine-tuned to partner drugs or LDTs
- Fast to start, scalable to impact—pilots launch in weeks

[Partner With Us](https://zephyrai.bio/partners/)